ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.54
-0.09%
US Tech 100
19,220.00
-0.20%
S&P 500
5,464.62
-0.16%
US Dollar vs CAD
1.36995
0.00%
Bitcoin
64,034.97
-0.33%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Purple Biotech Ltd (PPBT)

  7. Purple Biotech Ltd (PPBT) News

PPBT

Purple Biotech (PPBT)

Purple Biotech Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PPBT
DateTimeSourceHeadlineSymbolCompany
06/20/20248:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
06/04/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
06/03/20245:21AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
06/01/20247:00AMGlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
05/21/20246:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
05/21/20246:30AMGlobeNewswire Inc.Purple Biotech Reports First Quarter 2024 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
04/25/20246:00AMGlobeNewswire Inc.Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingNASDAQ:PPBTPurple Biotech Ltd
03/28/20246:00AMGlobeNewswire Inc.Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024NASDAQ:PPBTPurple Biotech Ltd
03/14/20246:30AMGlobeNewswire Inc.Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyNASDAQ:PPBTPurple Biotech Ltd
03/06/20243:06PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
03/05/20243:00PMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PPBTPurple Biotech Ltd
03/05/20246:58AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
03/05/20246:55AMGlobeNewswire Inc.Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
02/27/20246:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
02/27/20246:00AMGlobeNewswire Inc.Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024NASDAQ:PPBTPurple Biotech Ltd
02/13/20246:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
02/13/20246:00AMGlobeNewswire Inc.Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialNASDAQ:PPBTPurple Biotech Ltd
02/01/20246:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
02/01/20246:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
02/01/20246:30AMGlobeNewswire Inc.Purple Biotech Reaches Recommended Phase 2 Dose for NT219NASDAQ:PPBTPurple Biotech Ltd
01/26/20243:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
12/20/20237:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
12/20/20237:05AMGlobeNewswire Inc.Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsNASDAQ:PPBTPurple Biotech Ltd
12/14/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
12/14/20235:50AMGlobeNewswire Inc.Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialNASDAQ:PPBTPurple Biotech Ltd
11/21/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
11/21/20235:50AMGlobeNewswire Inc.Purple Biotech Reports Third Quarter 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
11/14/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PPBTPurple Biotech Ltd
11/14/20233:13PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PPBTPurple Biotech Ltd
11/13/20233:11PMEdgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:PPBTPurple Biotech Ltd
 Showing the most relevant articles for your search:NASDAQ:PPBT

Your Recent History

TG
A3LBF5
Denmark
TG
AEC1
American Express
COIN
2LCBTC
2local Token
LSE
15XY
Barclays 42
TG
A19GVQ
Credit Agricole London
LSE
JIGI
NASDAQ
AAYAWXX
Barclays Bank Plc Point ...
LSE
36EN
Port.tel.4.50%
USOTC
TXCB
Cang Bao Tian Xia Intern... (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved